Novel recombinant bi-functional fusion protein, preparation method therefor and use thereof
AssigneeImmuneonco Biopharmaceuticals (Shanghai) Inc.
InventorsWenzhi Tian, Song Li
Life of this patent
Estimating the term…
Abstract
Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRPα. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRPα interaction such that macrophages are activated to attack tumor cells, The bi-functional fusion protein has evident anti-tumor activities.
Claims14
A recombinant bi-functional fusion protein, comprising an antibody or an antibody fragment specifically binding to CD20, and a peptide specifically binding to CD47,
- wherein the peptide is linked to the antibody or the antibody fragment,
- wherein the antibody or antibody fragment specifically binding to CD20 comprises a heavy chain variable region of SEQ ID NO.:
- 5, and the light chain contains a light chain variable region of SEQ ID NO.:
- 7 and
- wherein the peptide specifically binding to CD47 comprises a sequence having at least 95% identity to SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.